1Lax SF, Kendall B, Tashiro H, et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma. Evidence of distinct molecular genetic pathways. Cancer, 2000,88:814-824.
2Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecologic malignancies. Cancer Res, 1997, 57: 3935-3940.
3Kong D, Suzuki A, Zou T, et al. PTEN is frequently mutated in primary endometrial carcinomas. Nat Genet, 1997, 17: 143-144.
4Risinger JI, Hayes K, Maxwell GL, et al. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res, 1998, 4: 3005-3010.
5Geisler JP, Geisler HE, Wiemann MC, et al. P53 expression as a prognostic indicator of 5-year survival in endometrial cancer. Gynecol Oncol, 1999, 74:468-471.
6Bockman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol, 1983, 15: 10-17.
9Salvesen HB, Stefansson I, Kalvens M B, et al. Loss of PTEN expression is associated with metastatic disease inpatients with endometrial carcinoma [ J ]. Cancer,2002,94 ( 6 ) : 2185 - 2191.
10Levine RL,Carglile CB,Blazes MS,et al. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrial carcinoma [ J]. Cancer Res, 1998,58 (8) :3254.
